In preclinical experiments, seribantumab prevented the activation of HER3 signaling in cells that harbor an NRG1 gene fusion. In addition to extensive nonclinical characterization and testing ...

effectively and synergistically inhibits EGFR/HER3 downstream signaling, leading to further inhibition of tumor growth. Its lead compound demonstrated favorable stability and a PK profile ...

HER3 expression was... significantly associated with decreased disease-specific survival HER2 cellular signaling is affected by the expression of other type 1 growth factor receptor family members ...

Figure 1: Key signaling pathways and targeted factors ... oncogenesis by activating the MAPK and PI3K/Akt pathways, with HER3 and HER4 modulating these signals. The PI3K/Akt/mTOR pathway controls ...

In the latest recitation, Bristol-Myers Squibb is paying $800 million upfront for rights to a HER3-directed ADC from China’s SystImmune in a deal that could swell to $8.4 billion. It gives BMS ...

Daiichi Sankyo has been granted breakthrough status by the FDA for patritumab deruxtecan, a HER3-targeted antibody-drug conjugate (ADC) in clinical trials for lung cancer. The designation ...

From April 25 to 30, 2025, the American Association for Cancer Research (AACR) Annual Meeting will take place in Chicago. CStone will showcase its latest preclinical studies on five internally ...